Financials in USD. Standardized financial statements.
A compact view of how BioMarin Pharmaceutical Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B |
| Revenue Growth? | +12.9% | +18.0% | +15.4% | +13.5% | -0.8% | +9.2% | +14.3% | +13.5% | +17.6% | 0.0% |
| Cost of Revenue? | $736.83M | $580.24M | $532.06M | $503.02M | $470.51M | $524.27M | $359.47M | $315.26M | $241.79M | $209.62M |
| Gross Profit? | $2.48B | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B | $1.34B | $1.18B | $1.07B | $907.23M |
| Gross Margin? | +77.1% | +79.7% | +78.0% | +76.0% | +74.5% | +71.8% | +78.9% | +78.9% | +81.6% | +81.2% |
| Operating Expenses? | $1.95B | $1.79B | $1.70B | $1.43B | $1.46B | $1.38B | $1.45B | $1.30B | $1.09B | $1.71B |
| Operating Income? | $533.48M | $484.21M | $185.77M | $160.97M | -$82.34M | -$43.44M | -$100.46M | -$123.52M | -$14.70M | -$803.43M |
| EBITDA? | $572.94M | $650.53M | $306.77M | $265.36M | $47.43M | $83.66M | $31.92M | -$3.37M | $90.97M | -$698.01M |
| Income Before Tax | $482.48M | $541.76M | $188.56M | $149.58M | -$75.35M | -$49.00M | -$94.81M | -$142.71M | -$35.88M | -$831.05M |
| Income Tax Expense | $133.58M | $114.90M | $20.92M | $8.02M | -$11.27M | -$903.03M | -$70.96M | -$65.49M | $81.17M | -$200.84M |
| Net Income? | $348.90M | $426.86M | $167.65M | $141.56M | -$64.08M | $854.03M | -$23.85M | -$77.21M | -$117.04M | -$630.21M |
| EPS? | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.75 | $-0.13 | $-0.44 | $-0.67 | $-3.80 |
| Diluted EPS? | $1.80 | $2.21 | $0.88 | $0.75 | $-0.35 | $4.53 | $-0.13 | $-0.44 | $-0.67 | $-3.79 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality